728 related articles for article (PubMed ID: 3293762)
1. A prospective randomized trial of HLA-matched versus mismatched single-donor platelet transfusions in cancer patients.
Messerschmidt GL; Makuch R; Appelbaum F; Ungerleider RS; Abrams R; O'Donnell J; Holohan TV; Fontana J; Wright D; Anagnou NP
Cancer; 1988 Aug; 62(4):795-801. PubMed ID: 3293762
[TBL] [Abstract][Full Text] [Related]
2. ABO compatibility can influence the results of platelet transfusion. Results of a randomized trial.
Lee EJ; Schiffer CA
Transfusion; 1989 Jun; 29(5):384-9. PubMed ID: 2660333
[TBL] [Abstract][Full Text] [Related]
3. Platelet transfusion therapy. One-hour posttransfusion increments are valuable in predicting the need for HLA-matched preparations.
Daly PA; Schiffer CA; Aisner J; Wiernik PH
JAMA; 1980 Feb; 243(5):435-8. PubMed ID: 7351763
[TBL] [Abstract][Full Text] [Related]
4. The transfusion of HLA-matched platelets to thrombocytopenic patients resistant to random donor platelets.
Levy L; Woodfield DG
N Z Med J; 1984 Oct; 97(766):719-21. PubMed ID: 6595558
[TBL] [Abstract][Full Text] [Related]
5. HLAMatchmaker is effective for selecting appropriate platelet units for alloimmunised thrombocytopaenic patients who are refractory to random donor platelets.
O'Rafferty C; Rooney G; Hagan R; Woolfson M; O'Donghaile D; Fitzgerald J
Transfus Med; 2017 Oct; 27 Suppl 5():369-374. PubMed ID: 28393455
[TBL] [Abstract][Full Text] [Related]
6. Use of in vitro assays in selection of compatible platelet donors.
Tosato G; Appelbaum FR; Trapani RJ; Dowling R; Deisseroth AB
Transfusion; 1980; 20(1):47-54. PubMed ID: 7355471
[TBL] [Abstract][Full Text] [Related]
7. Successful transfusion of platelets "mismatched" for HLA antigens to alloimmunized thrombocytopenic patients.
Duquesnoy RJ; Filip DJ; Rodey GE; Rimm AA; Aster RH
Am J Hematol; 1977; 2(3):219-26. PubMed ID: 596366
[TBL] [Abstract][Full Text] [Related]
8. An epitope-based approach of HLA-matched platelets for transfusion: a noninferiority crossover randomized trial.
Marsh JC; Stanworth SJ; Pankhurst LA; Kallon D; Gilbertson AZ; Pigden C; Deary AJ; Mora AS; Brown J; Laing ES; Choo LL; Hodge R; Llewelyn CA; Harding K; Sage D; Mijovic A; Mufti GJ; Navarrete CV; Brown CJ
Blood; 2021 Jan; 137(3):310-322. PubMed ID: 33475737
[TBL] [Abstract][Full Text] [Related]
9. Delayed alloimmunisation by random single donor platelet transfusions. A randomised study to compare single donor and multiple donor platelet transfusions in cancer patients with severe thrombocytopenia.
Sintnicolaas K; Vriesendorp HM; Sizoo W; Stenfert Kroese WF; Haije WG; Hop WC; Abels J; Löwenberg B
Lancet; 1981 Apr; 1(8223):750-4. PubMed ID: 6110956
[TBL] [Abstract][Full Text] [Related]
10. Pathogen-reduced platelets for the prevention of bleeding.
Butler C; Doree C; Estcourt LJ; Trivella M; Hopewell S; Brunskill SJ; Stanworth S; Murphy MF
Cochrane Database Syst Rev; 2013 Mar; (3):CD009072. PubMed ID: 23543569
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation.
Estcourt L; Stanworth S; Doree C; Hopewell S; Murphy MF; Tinmouth A; Heddle N
Cochrane Database Syst Rev; 2012 May; (5):CD004269. PubMed ID: 22592695
[TBL] [Abstract][Full Text] [Related]
12. Platelet transfusion therapy for alloimmunized patients: selective mismatching for HLA B12, an antigen with variable expression on platelets.
Schiffer CA; O'Connell B; Lee EJ
Blood; 1989 Aug; 74(3):1172-6. PubMed ID: 2752158
[TBL] [Abstract][Full Text] [Related]
13. HLA-matched platelet transfusions are effective only in refractory patients with positive HLA antibody screening.
Kreuger AL; Mäkelburg ABU; Somers JAE; Tomson B; van de Watering LMG; van der Bom JG; van Kraaij MGJ; Weller CM
Transfusion; 2019 Nov; 59(11):3303-3307. PubMed ID: 31602653
[TBL] [Abstract][Full Text] [Related]
14. HLA class I-eluted platelets as an alternative to HLA-matched platelets.
Novotny VM; Huizinga TW; van Doorn R; Briët E; Brand A
Transfusion; 1996 May; 36(5):438-44. PubMed ID: 8693509
[TBL] [Abstract][Full Text] [Related]
15. HLA-selected platelets for platelet refractory patients with HLA antibodies: a single-center experience.
Karlström C; Linjama T; Edgren G; Lauronen J; Wikman A; Höglund P
Transfusion; 2019 Mar; 59(3):945-952. PubMed ID: 30575964
[TBL] [Abstract][Full Text] [Related]
16. Management of bleeding in a multi-transfused patient with positive HLA class I alloantibodies and thrombocytopenia associated with platelet dysfunction refractory to transfusion of cross-matched platelets.
Heuer L; Blumenberg D
Blood Coagul Fibrinolysis; 2005 Jun; 16(4):287-90. PubMed ID: 15870549
[TBL] [Abstract][Full Text] [Related]
17. Transfusion of ABO-mismatched platelets leads to early platelet refractoriness.
Carr R; Hutton JL; Jenkins JA; Lucas GF; Amphlett NW
Br J Haematol; 1990 Jul; 75(3):408-13. PubMed ID: 2201403
[TBL] [Abstract][Full Text] [Related]
18. The impact of platelet transfusion characteristics on posttransfusion platelet increments and clinical bleeding in patients with hypoproliferative thrombocytopenia.
Triulzi DJ; Assmann SF; Strauss RG; Ness PM; Hess JR; Kaufman RM; Granger S; Slichter SJ
Blood; 2012 Jun; 119(23):5553-62. PubMed ID: 22496156
[TBL] [Abstract][Full Text] [Related]
19. Fatal graft-versus-host disease associated with transfusions of HLA-matched, HLA-homozygous platelets from unrelated donors.
Benson K; Marks AR; Marshall MJ; Goldstein JD
Transfusion; 1994 May; 34(5):432-7. PubMed ID: 8191569
[TBL] [Abstract][Full Text] [Related]
20. Platelet transfusion from donors mismatched for crossreactive HLA antigens.
Dahlke MB; Weiss KL
Transfusion; 1984; 24(4):299-302. PubMed ID: 6464151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
